When the White House announced voluntary pricing agreements with major pharmaceutical manufacturers, deals promising to align what Americans pay with the lowest prices those same companies charge abroad, it was framed as a turning point. The administration called it the greatest victory for patient affordability in the history of American health care.
Then January arrived. Here is what really happened.
